Switch theme
Sign up to access all valuation multiples
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.
1991
223
Last FY Revenue $172M
Last FY EBITDA $3.9M
$5.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Farmaceutica Remedia achieved revenue of $172M and an EBITDA of $3.9M.
Farmaceutica Remedia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Farmaceutica Remedia valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $172M | XXX | XXX | XXX |
| Gross Profit | XXX | $13.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 8% | XXX | XXX | XXX |
| EBITDA | XXX | $3.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 2% | XXX | XXX | XXX |
| EBIT | XXX | $3.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 2% | XXX | XXX | XXX |
| Net Profit | XXX | $1.6M | XXX | XXX | XXX |
| Net Margin | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 30, 2025, Farmaceutica Remedia's stock price is RON 1 (or $0).
Farmaceutica Remedia has current market cap of RON 70.8M (or $16.3M), and EV of RON 24.0M (or $5.5M).
See Farmaceutica Remedia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.5M | $16.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 30, 2025, Farmaceutica Remedia has market cap of $16.3M and EV of $5.5M.
Farmaceutica Remedia's trades at 0.0x EV/Revenue multiple, and 1.4x EV/EBITDA.
Equity research analysts estimate Farmaceutica Remedia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Farmaceutica Remedia's P/E ratio is not available.
See valuation multiples for Farmaceutica Remedia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.3M | XXX | $16.3M | XXX | XXX | XXX |
| EV (current) | $5.5M | XXX | $5.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 1.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 10.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFarmaceutica Remedia's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $46K for the same period.
Farmaceutica Remedia's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Farmaceutica Remedia's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Farmaceutica Remedia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $46K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma Trading | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Farmaceutica Remedia acquired XXX companies to date.
Last acquisition by Farmaceutica Remedia was XXXXXXXX, XXXXX XXXXX XXXXXX . Farmaceutica Remedia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Farmaceutica Remedia founded? | Farmaceutica Remedia was founded in 1991. |
| Where is Farmaceutica Remedia headquartered? | Farmaceutica Remedia is headquartered in Romania. |
| How many employees does Farmaceutica Remedia have? | As of today, Farmaceutica Remedia has 223 employees. |
| Is Farmaceutica Remedia publicy listed? | Yes, Farmaceutica Remedia is a public company listed on BSE. |
| What is the stock symbol of Farmaceutica Remedia? | Farmaceutica Remedia trades under RMAH ticker. |
| When did Farmaceutica Remedia go public? | Farmaceutica Remedia went public in 2006. |
| Who are competitors of Farmaceutica Remedia? | Similar companies to Farmaceutica Remedia include e.g. Ansell, Polymed, Etropal, Sopharma. |
| What is the current market cap of Farmaceutica Remedia? | Farmaceutica Remedia's current market cap is $16.3M |
| Is Farmaceutica Remedia profitable? | Yes, Farmaceutica Remedia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
